Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
Bioengineered
; 11(1): 824-828, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32772769
ABSTRACT
CAR-T cells therapy can give rise to most common and concerning two side effects - cytokine release syndrome (CRS) and neurotoxicity. But in our CD19 CAR-T cells therapy clinical trial, we observed 1 out of 17 patients with B-cell acute lymphoblastic leukemia (B-ALL) developed acute myelofibrosis(AMF) after grade IV CRS post to the CD19 CAR-T cells therapy. This finding suggests that the CAR-T cells therapy may have rare and serious AMF, which we should pay important attention to. Trial registrationNCT02968472. Registered 18 November 2016 - Retrospectively registered, https//clinicaltrials.gov/ct2/show/NCT02968472.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia Adotiva
/
Antígenos CD19
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Mielofibrose Primária
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article